一线单倍体造血干细胞移植联合无关脐血输注与一线免疫抑制治疗获得性重型再生障碍性贫血的疗效及健康相关生活质量比较
该回顾性研究比较了一线单倍体造血干细胞移植联合无关脐血输注(haplo-HSCT组,n=146)与一线免疫抑制治疗(IST组,n=219)在获得性重型再生障碍性贫血患者中的疗效和健康相关生活质量。治疗后6个月,haplo-HSCT组90.30%患者、IST组18.78%患者达到血常规正常(P<0.0001)。4年无失败生存率haplo-HSCT组为77.8±3.7%、IST组为48.0±3.6%(P<0.0001),且haplo-HSCT组健康相关生活质量评分显著更优(P<0.0001)。
要点
- 治疗后6个月血常规正常率:haplo-HSCT组90.30% vs IST组18.78%(P<0.0001)。
- 4年无失败生存率:haplo-HSCT组77.8±3.7% vs IST组48.0±3.6%(P<0.0001)。
- 4年总生存率两组相似:haplo-HSCT组80.1±3.5% vs IST组80.1±3.0%(P=0.726)。
核心结论
- 一线单倍体造血干细胞移植联合无关脐血输注可能较一线免疫抑制治疗为重型再生障碍性贫血患者提供更好的成功机会和健康相关生活质量。
研究设计与样本
- 回顾性比较研究,纳入获得性重型再生障碍性贫血患者,一线单倍体造血干细胞移植联合无关脐血输注组146例,一线免疫抑制治疗组219例。
主要发现
- 治疗后6个月达到血常规正常的患者比例:haplo-HSCT组90.30% vs IST组18.78%(P<0.0001)。
- IST组停用红细胞和血小板输注所需时间均长于haplo-HSCT组(P<0.0001)。
- 4年估算总生存率:haplo-HSCT组80.1±3.5% vs IST组80.1±3.0%(P=0.726)。
- 4年估算无失败生存率:haplo-HSCT组77.8±3.7% vs IST组48.0±3.6%(P<0.0001)。
- 健康相关生活质量评分haplo-HSCT组显著优于IST组(P<0.0001);多因素分析中一线haplo-HSCT是无失败生存率和健康相关生活质量的有利因素(P<0.0001)。
关键数值与推荐
- 治疗后6个月血常规正常率:haplo-HSCT组90.30% vs IST组18.78%(P<0.0001)。
- 4年估算总生存率:haplo-HSCT组80.1±3.5% vs IST组80.1±3.0%(P=0.726)。
- 4年估算无失败生存率:haplo-HSCT组77.8±3.7% vs IST组48.0±3.6%(P<0.0001)。
临床怎么用
- 原文结论提示,对于获得性重型再生障碍性贫血患者,一线单倍体造血干细胞移植联合无关脐血输注可能较一线免疫抑制治疗提供更好的成功机会和健康相关生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively compared the efficacy and health-related quality of life (HRQoL) of (1) first-line haploidentical hematopoietic stem cell transplantation (haplo-HSCT, n = 146) combined with unrelated cord blood (UCB) infusion and (2) first-line immunosuppressive therapy (IST, n = 219) in acquired severe aplastic anemia (SAA) patients. At 6 months post treatment, 90.30% patients in the haplo-HSCT group and 18.78% patients in the IST group achieved normal blood routine (P < 0.0001). The time required to discontinue red blood cells and platelets transfusion in the IST group were longer than in the haplo-HSCT group (P < 0.0001). The estimated overall survival at 4 years was similar (80.1 ± 3.5% vs. 80.1 ± 3.0%, P = 0.726); the estimated failure-free survival (FFS) at 4 years was 77.8 ± 3.7% in the haplo-HSCT group and 48.0 ± 3.6% in the IST group (P < 0.0001). Patients treated with haplo-HSCT scored significantly better in the HRQoL than treated with IST (P < 0.0001). In the multivariate analysis, first-line haplo-HSCT was the favorable factor for FFS and HRQoL (P < 0.0001). These results suggest that first-line haplo-HSCT combined with UCB infusion might provide a better chance of success and HRQoL than first-line IST for SAA patients.
引用
- Liu L, Zhang Y, Jiao W, et al. Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. Leukemia. 2020. PMID: 32591644. doi:10.1038/s41375-020-0933-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。